ADC	Solid tumor indication (line)	Target antigen	Linker type (DAR)	Cytotoxic payload (payload action)	Country (date of approval)	MAH	Pivotal trial(s) (Phase: Clinical trial identifier)	Ref(s)
Trastuzumab emtansine	Locally advanced or metastatic HER2+ BC (≥2L)	HER2	Non-cleavable thioether linker (DAR 3−4)	Emtansine/DM1 (microtubule inhibitor)	US (Feb 2013); Switzerland (May 2013); EU (Sept 2013)	Genentech/Roche	EMILIA (phase III: NCT00829166)	[@111503]
	Early HER2+ BC post-neoadjuvant with no pCR				US (May 2019); EU (Nov 2019); Switzerland (Jan 2020)		KATHERINE (phase III: NCT01772472)	[@111504]
Trastuzumab deruxtecan*	Unresectable or metastatic HER2+ BC (≥2L)	HER2	Enzyme cleavable tetrapeptide-based linker (DAR 8)	Deruxtecan (topoisomerase inhibitor)	US (Aug 2019); EU (Dec 2020); Switzerland (Nov 2021)	Daiichi Sankyo/AstraZeneca	DESTINY-Breast01 (phase II: NCT03248492)	[@111515]
	locally advanced or metastatic HER2+ G/GEJ adenocarcinoma				US (Jan 2021)		DESTINY-Gastric01 (phase II: NCT03329690)	[@111576]
Sacituzumab govitecan*	Metastatic TN BC (≥2L)	Trop-2	Acid cleavable CL2A peptide linker (DAR 7.6)	Govitecan/SN-38 (topoisomerase inhibitor)	US (Apr 2020); EU (Oct 2021); Switzerland (Sept 2021)	Gilead Sciences	ASCENT (phase III: NCT02574455)	[@111505]
	Locally advanced or metastatic UC (≥2L)				US (Apr 2021)		TROPHY U-01 (phase II: NCT03547973); TROPiCS-04 (phase III: NCT04527991)	[@111514]
Enfortumab vedotin*	Locally advanced or metastatic UC (≥2L)	Nectin-4	Enzyme cleavable valine-citrulline linker (DAR 4)	MMAE (microtubule inhibitor)	US (Dec 2019); Switzerland (Nov 2021)	Astellas/Seagen Inc.	EV-301 (phase III: NCT03474107)	[@111577]
Tisotumab vedotin*	Recurrent or metastatic CC (≥2L)	Tissue factor	Enzyme cleavable linker (DAR 4)	MMAE (microtubule inhibitor)	US (Sept 2021)	Seagen Inc.	InnovaTV 204 (phase II: NCT03438396)	[@111524]